RU2570554C2 - Гуманизированные моноклональные антитела к сеа с созревшей аффинностью - Google Patents

Гуманизированные моноклональные антитела к сеа с созревшей аффинностью Download PDF

Info

Publication number
RU2570554C2
RU2570554C2 RU2012112340/10A RU2012112340A RU2570554C2 RU 2570554 C2 RU2570554 C2 RU 2570554C2 RU 2012112340/10 A RU2012112340/10 A RU 2012112340/10A RU 2012112340 A RU2012112340 A RU 2012112340A RU 2570554 C2 RU2570554 C2 RU 2570554C2
Authority
RU
Russia
Prior art keywords
afm
seq
cea
sequence
antibody
Prior art date
Application number
RU2012112340/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2012112340A (ru
Inventor
У. ХОФЕР Томас
ХОССЕ Ральф
МЁССНЕР Эккехард
УМАНА Пабло
Original Assignee
Роше Гликарт Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2570554(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Роше Гликарт Аг filed Critical Роше Гликарт Аг
Publication of RU2012112340A publication Critical patent/RU2012112340A/ru
Application granted granted Critical
Publication of RU2570554C2 publication Critical patent/RU2570554C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2012112340/10A 2009-08-31 2010-08-27 Гуманизированные моноклональные антитела к сеа с созревшей аффинностью RU2570554C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23850509P 2009-08-31 2009-08-31
US61/238,505 2009-08-31
PCT/EP2010/062527 WO2011023787A1 (en) 2009-08-31 2010-08-27 Affinity-matured humanized anti cea monoclonal antibodies

Publications (2)

Publication Number Publication Date
RU2012112340A RU2012112340A (ru) 2013-10-10
RU2570554C2 true RU2570554C2 (ru) 2015-12-10

Family

ID=42985489

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012112340/10A RU2570554C2 (ru) 2009-08-31 2010-08-27 Гуманизированные моноклональные антитела к сеа с созревшей аффинностью

Country Status (22)

Country Link
US (2) US9068008B2 (enExample)
EP (1) EP2473532B1 (enExample)
JP (1) JP5744872B2 (enExample)
KR (1) KR101528013B1 (enExample)
CN (1) CN102741293B (enExample)
AR (1) AR078111A1 (enExample)
AU (1) AU2010288469A1 (enExample)
BR (1) BR112012003983A2 (enExample)
CA (1) CA2770174A1 (enExample)
CL (1) CL2012000551A1 (enExample)
CO (1) CO6491105A2 (enExample)
CR (1) CR20120087A (enExample)
EC (1) ECSP12011698A (enExample)
IL (1) IL218038A0 (enExample)
MA (1) MA33536B1 (enExample)
MX (1) MX339608B (enExample)
PE (1) PE20121552A1 (enExample)
RU (1) RU2570554C2 (enExample)
SG (1) SG178567A1 (enExample)
TW (1) TW201121994A (enExample)
WO (1) WO2011023787A1 (enExample)
ZA (1) ZA201200954B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12091461B2 (en) 2018-02-09 2024-09-17 Ono Pharmaceutical Co., Ltd. Bispecific antibody

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5992710A (ja) * 1982-11-16 1984-05-29 関西電力株式会社 直接水冷線路の立坑部の布設方法
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
RU2013139267A (ru) 2011-02-10 2015-03-20 Рош Гликарт Аг Улучшенная иммунотерапия
ES2657856T3 (es) * 2011-03-02 2018-03-07 Roche Glycart Ag Anticuerpos CEA
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP3321286B1 (en) 2011-08-23 2021-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
EP2747781B1 (en) 2011-08-23 2017-11-15 Roche Glycart AG Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
MY171038A (en) 2011-08-23 2019-09-23 Roche Glycart Ag Bispecific antigen binding molecules
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
GB201213858D0 (en) 2012-08-03 2012-09-19 Mab Design Ltd Method
AR092044A1 (es) 2012-08-07 2015-03-18 Roche Glycart Ag Inmunoterapia mejorada
WO2014056783A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
WO2014131712A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2014131711A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
JP6499087B2 (ja) 2013-02-26 2019-04-10 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
MX366359B (es) 2014-04-27 2019-07-05 Ccam Biotherapeutics Ltd Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
RS65573B1 (sr) 2014-08-04 2024-06-28 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije
FI4141032T3 (fi) 2014-11-20 2024-07-31 Hoffmann La Roche T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito
BR112017010513A2 (pt) 2014-11-20 2018-04-03 F. Hoffmann-La Roche Ag ?cadeias leves comuns e métodos de uso?
EP3221356B1 (en) 2014-11-20 2020-09-02 F.Hoffmann-La Roche Ag T cell activating bispecific antigen binding molecules against folr1 and cd3
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
KR20180073561A (ko) 2015-10-02 2018-07-02 에프. 호프만-라 로슈 아게 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
AU2016368469B2 (en) 2015-12-09 2023-11-02 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
LT3433280T (lt) 2016-03-22 2023-07-10 F. Hoffmann-La Roche Ag Proteazės aktyvuojamos t ląstelei bispecifinės molekulės
CN107663240B (zh) * 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
US10882918B2 (en) 2016-09-30 2021-01-05 Hoffmann-La Roche Inc. Bispecific T cell activating antigen binding molecules
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
CA3141378A1 (en) 2019-06-26 2020-12-30 F. Hoffmann-La Roche Ag Fusion of an antibody binding cea and 4-1bbl
WO2020259550A1 (zh) * 2019-06-26 2020-12-30 江苏恒瑞医药股份有限公司 抗cea抗体及其应用
CN110713539B (zh) * 2019-09-23 2021-04-16 华道(上海)生物医药有限公司 一种抗癌胚抗原的抗体及其制备方法和用途
CN110862456B (zh) * 2019-09-23 2021-04-09 华道(上海)生物医药有限公司 一种抗癌胚抗原的抗体及其制备方法和用途
TWI852680B (zh) 2020-06-19 2024-08-11 瑞士商赫孚孟拉羅股份公司 與 cd3 及 cd19 結合之抗體
EP4097486A4 (en) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF POSITIVE CANCERS AT CEACAM
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
WO2022228705A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
JP2024519078A (ja) * 2021-05-21 2024-05-08 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｃｅａ抗体及びその使用方法
EP4469474A4 (en) * 2022-01-27 2026-05-20 Janssen Biotech Inc IMPROVED PROTEIN COMPOSITIONS
KR20250024741A (ko) 2022-03-23 2025-02-19 시나픽스 비.브이. 암배아성 항원을 발현하는 종양을 표적화하기 위한 항체-컨쥬게이트
TW202506733A (zh) 2023-06-12 2025-02-16 美商安進公司 淋巴毒素β受體促效劑結合蛋白
WO2025257185A1 (en) * 2024-06-11 2025-12-18 Abcely Humanized anti-human-carcinoembryonic antigen antibody

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2122431C1 (ru) * 1992-05-07 1998-11-27 Никомед Имеджинг Ас Радиоактивный иммунореагент направленного действия, композиция для получения изображения злокачественного новообразования в организме, способ получения изображения и комплексообразующий агент
US20070166309A1 (en) * 2002-09-27 2007-07-19 Xencor, Inc. Optimized anti-cd30 antibodies
US20080146784A1 (en) * 2002-08-01 2008-06-19 Immunomedics, Inc. Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
GB9317423D0 (en) 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
NZ523912A (en) 2000-07-31 2005-03-24 Biolex Inc Expression of biologically active polypeptides in duckweed
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6815175B2 (en) * 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP2359685B1 (en) 2001-12-27 2013-12-04 GlycoFi, Inc. Methods to engineer mammalian-type carbohydrate structures
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP2319935B1 (en) 2002-03-19 2016-04-27 Stichting Dienst Landbouwkundig Onderzoek GnTIII (UDP-N-acetylglucosamine:Beta -D mannoside Beta (1,4)-N-acetylglucosaminyltransferase III) expression in plants.
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
EP1539966B1 (en) 2002-09-12 2010-06-30 Greenovation Biotech GmbH Protein production method
WO2004057002A2 (en) 2002-12-20 2004-07-08 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CZ308720B6 (cs) 2003-01-22 2021-03-24 Roche Glycart Ag Fúzní konstrukty a jejich použití pro přípravu protilátek se zvýšenou vazebnou afinitou k receptorům Fc a efektorovou funkcí
US20090005257A1 (en) * 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
ES2657856T3 (es) * 2011-03-02 2018-03-07 Roche Glycart Ag Anticuerpos CEA

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2122431C1 (ru) * 1992-05-07 1998-11-27 Никомед Имеджинг Ас Радиоактивный иммунореагент направленного действия, композиция для получения изображения злокачественного новообразования в организме, способ получения изображения и комплексообразующий агент
US20080146784A1 (en) * 2002-08-01 2008-06-19 Immunomedics, Inc. Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof
US20070166309A1 (en) * 2002-09-27 2007-07-19 Xencor, Inc. Optimized anti-cd30 antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WILKINSON R.W. et al, Evaluation of a Transgenic Mouse Model for Anti-Human CEA Radioimmunotherapeutics, J Nucl Med., 2002, n. 10, vol. 43, pp.1368-1376. *
Yafang L. et al, Role of Estrogen Receptor-α in the Regulation of Claudin-6 Expression in Breast Cancer Cells, J Breast Cancer 2011, n.14(1), pp.20-27. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12091461B2 (en) 2018-02-09 2024-09-17 Ono Pharmaceutical Co., Ltd. Bispecific antibody

Also Published As

Publication number Publication date
BR112012003983A2 (pt) 2021-09-14
CL2012000551A1 (es) 2012-10-12
MA33536B1 (fr) 2012-08-01
HK1176951A1 (en) 2013-08-09
RU2012112340A (ru) 2013-10-10
TW201121994A (en) 2011-07-01
PE20121552A1 (es) 2012-11-26
US20110104148A1 (en) 2011-05-05
CN102741293B (zh) 2015-04-01
US20160075795A1 (en) 2016-03-17
JP5744872B2 (ja) 2015-07-08
MX2012002461A (es) 2012-03-14
KR20120060874A (ko) 2012-06-12
WO2011023787A1 (en) 2011-03-03
US9068008B2 (en) 2015-06-30
CN102741293A (zh) 2012-10-17
CA2770174A1 (en) 2011-03-03
IL218038A0 (en) 2012-04-30
AR078111A1 (es) 2011-10-12
AU2010288469A1 (en) 2012-03-01
CR20120087A (es) 2012-03-22
ECSP12011698A (es) 2012-03-30
KR101528013B1 (ko) 2015-06-16
EP2473532A1 (en) 2012-07-11
CO6491105A2 (es) 2012-07-31
MX339608B (es) 2016-05-31
JP2013502913A (ja) 2013-01-31
SG178567A1 (en) 2012-04-27
EP2473532B1 (en) 2017-06-21
ZA201200954B (en) 2014-07-30

Similar Documents

Publication Publication Date Title
US20230365711A1 (en) Anti-cea antibodies
US9068008B2 (en) Antibodies to carcinoembryonic antigen (CEA), methods of making same, and uses thereof
AU2007282923B2 (en) Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
US20060223096A1 (en) Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function
HK1176951B (en) Affinity-matured humanized anti cea monoclonal antibodies
HK1187056B (zh) 抗cea抗体